AI-assisted breast cancer screening showed minor clinical benefits over DBT alone but was not cost-effective at standard willingness-to-pay thresholds.
Key Details
- 1Study published in Value in Health evaluated the cost-effectiveness of AI (Saige-DX) in breast cancer screening.
- 2Microsimulation compared digital breast tomosynthesis (DBT) alone and DBT plus AI for women aged 40–74 in biennial screening.
- 3AI reduced false negatives by 2.1 and false positives by 50 per 1,000 women; 0.13 fewer breast cancer deaths per 1,000.
- 4AI-assisted screening led to 3.09 additional QALYs but added $936,430 in lifetime costs per 1,000 women (ICER: $303,279/QALY).
- 5AI was not cost-effective at a $100,000/QALY threshold in 98% of simulations, mainly due to 21% increase in DCIS diagnoses.
- 6Cost-effectiveness did not improve even at very low AI pricing in most scenarios.
Why It Matters
Although AI can modestly improve accuracy in breast cancer screening, this study highlights persistent cost-effectiveness concerns, especially with increased DCIS detection. This underscores an economic and clinical challenge for broader AI adoption in screening workflows.
Source
AuntMinnie
Related News
•Radiology Business
AI-Powered Tool Streamlines CT Scan Prioritization in Emergency Departments
An AI-based CT queue system significantly reduces wait times for ED patients by prioritizing scans likely to reveal critical findings.
•Radiology Business
AI Workflow Enables General Radiologists to Match Breast Specialists in Screening
AI-powered workflow helps generalist radiologists detect breast cancer at rates comparable to specialists.
•Radiology Business
LLMs Automate Radiology Report Quality Control, Study Finds
LLM-based systems can rapidly automate radiology report quality control, saving significant manual review time.